| Chairman |
|
Liu Yanjun |
| Business Nature |
| 醫療保健 (Health Care) |
| Board Members |
Chairman: Liu Yanjun
Chief Executive Officer: Wang Zheng
Executive Director: Li Cui
Employee Representative Director: Sun Yuhua
Non-executive Director: Lin Chia Ling, Diao Juanhuan, Li Chen
Independent Non-executive Director: Cai Zhongxi, Zeng Fanyi, Ju Dianwen, Zhang Senquan(Formerly known as Zhang Min).
|
| Principle Business |
|
The Group is principally engaged in biopharmaceutical business, focus on large-volume subcutaneous drug delivery, antibody-mediated autoimmune conditions, drugs in assisted reproduction and recombinant biologics. |
| Related Indexes | | Hang Seng Healthcare Index | Hang Seng Healthcare Industry Index | | Hang Seng Composite Index | Hang Seng Composite SmallCap Index |
|
| Major Shareholders |
| Liu Yanjun & ASSO | 78,540,230 | NON-H SHS | 24.09% | 45.75% | 2025/12/10 | | Center Laboratories, Inc. | 31,924,265 | NON-H SHS | 9.79% | 18.60% | 2025/12/10 | | Zheng Juan & ASSO | 21,661,110 | H Sh | 6.64% | 14.04% | 2025/12/10 | | Wang Zheng | 20,250,000 | NON-H SHS | 6.21% | 11.80% | 2025/12/10 | | Liu Yanjun & ASSO | 16,206,915 | H Sh | 4.97% | 10.50% | 2025/12/10 | | Shanghai Healthcare Capital Partnership | 8,871,510 | H Sh | 2.72% | 5.75% | 2025/12/10 | | Shanghai Xihao Investment Management Co., Ltd. | 8,319,280 | H Sh | 2.55% | 5.39% | 2025/12/10 | | Center Laboratories, Inc. | 7,981,065 | H Sh | 2.45% | 5.17% | 2025/12/10 | | Shanghai Healthcare Capital Partnership | 2,957,170 | NON-H SHS | 0.91% | 1.72% | 2025/12/10 | | Wang Zheng | 2,250,000 | H Sh | 0.69% | 1.46% | 2025/12/10 |
|
|
|
|
|